AbbVie shares have rallied 40.9% over the past year to trade at US$253.35, prompting a valuation review. A discounted cash flow analysis estimates intrinsic value at US$434.69 per share, suggesting the stock is 41.7% undervalued. However, AbbVie's price-to-earnings ratio stands at 124.51 times, well above the Simply Wall St fair ratio of 38.96 times, indicating overvaluation on that metric. Investor narratives on the platform incorporate developments such as the proposed US$10.9 billion Apogee Therapeutics acquisition, with fair value estimates ranging from US$184.00 to US$328.00.
AbbVie IncArticle discusses AbbVie's valuation after a 41% rally, with DCF suggesting undervaluation but P/E indicating overvaluation, and mentions the Apogee deal as context.
Apogee Therapeutics, Inc. Common StockAbbVie's proposed $10.9 billion acquisition of Apogee Therapeutics is mentioned, implying a positive valuation event for Apogee.